Andreea L Turcu, Júlia Companys-Alemany, Matthew B Phillips, Dhilon S Patel, Christian Griñán-Ferré, M Isabel Loza, José M Brea, Belén Pérez, David Soto, Francesc X Sureda, Maria G Kurnikova, Jon W Johnson, Mercè Pallàs, Santiago Vázquez
Currently, of the few accessible symptomatic therapies for Alzheimer's disease (AD), memantine is the only N-methyl-d-aspartate receptor (NMDAR) blocker approved by the FDA. This work further explores a series of memantine analogs featuring a benzohomoadamantane scaffold. Most of the newly synthesized compounds block NMDARs in the micromolar range, but with lower potency than previously reported hit IIc, results that were supported by molecular dynamics simulations. Subsequently, electrophysiological studies with the more potent compounds allowed classification of IIc, a low micromolar, uncompetitive, voltage-dependent, NMDAR blocker, as a memantine-like compound...
June 5, 2022: European Journal of Medicinal Chemistry